(TheNewswire)
VANCOUVER, BC. May 7, 2024 – TheNewswire – Aequus Pharmaceuticals Inc. (TSX-V: AQS , OTCQB: AQSZF ), ) (“Aequus” or the “Company”), a specialtypharmaceutical company, in response to the recent Canadian shortage of0.03% bimatoprost 1 , a critical active ingredient in treatmentof glaucoma, has increased supply of Zimed® PF 0.03% bimatoprost. Aequus Pharmaceuticals announces its commitment to meet the risingdemand for this first line glaucoma therapy drug. Recognizing theurgency of ensuring uninterrupted access to vital medications, Aequushas scaled up product supply in Canada to alleviate shortages faced bypatients.
With “Zimed® PF currently being the only availableglaucoma medication in the 0.03% bimatoprost format, we have startedsee an increase in demand and expect this to continue, and lead tohigher sales revenue in the coming months,” says Doug Janzen, CEO ofAequus Pharmaceuticals Canada. Zimed® PF with 0.03% bimatoprost hasthe additional benefit of being “Preservative Free” and availablein a patient friendly multi-dose eye drop format.
For more information, please visit www.ZimedPF.ca
1 www.drugshortagescanada.ca
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc. (TSX-V: AQS , OTCQB: AQSZF ) is a growing specialtypharmaceutical company focused on developing and commercializing highquality, differentiated products. Aequus, founded in 2015, hassuccessfully grown multiple products and brands in strategictherapeutic areas including Ophthalmology, Optometry, Transplant andRare Disease. Aequus plans to build on its Canadian commercialplatform through the application of sales, marketing and expertknowledge of the Canadian marketplace utilizing internal development,acquisition, or licenses with preferred strategic partners. Forfurther information, please visit www.aequuspharma.ca .
About Glaucoma, Dry Eye andZimed ® PF
Zimed ® PF is indicated for the reduction of elevated intraocularpressure (IOP) in patients with open-angle glaucoma or ocularhypertension. Glaucoma and elevated intraocular pressure can causevision loss or blindness by damaging the optic nerve located at theback of the eye. Dry eye disease is often associated with glaucoma dueto factors including age, environment, allergies, and preservatives ineyedrops. Zimed ® PF is the first preservative-free, multi-dose bottlebimatoprost available in Canada. Zimed ® PF(bimatoprost 0.03%) received market authorization from Health Canada in December2022.
Forward LookingStatements:
This release may containforward-looking statements or forward-looking information underapplicable Canadian securities legislation that may not be based onhistorical fact, including, without limitation, statements containingthe words “believe”, “may”, “plan”, “will”,“estimate”, “continue”, “anticipate”, “intend”,“expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptionsmade by us in light of our experience and perception of historicaltrends, current conditions and expected future developments, as wellas the factors we believe are appropriate. Forward-looking statements include but arenot limited to statements relating to: the implementation of ourbusiness model and strategic plans; revenue growth trends into thefuture; expected timing for product launches; the Company’s expectedrevenues; the regulatory approval of its products; the Company’sability to attract international partners; and ongoing discussionswith and the Company’sability to secure potential partners to further grow our productportfolio. Such statements reflect our current views with respect tofuture events and are subject to risks and uncertainties and arenecessarily based upon a number of estimates and assumptions that,while considered reasonable by Aequus, are inherently subject tosignificant business, economic, competitive, political and socialuncertainties and contingencies. Many factors could cause our actualresults, performance, or achievements to be materially different fromany future results, performance, or achievements that may be expressedor implied by such forward-looking statements. In making the forwardlooking statements included in this release, the Company has madevarious material assumptions, including, but not limited to: obtainingregulatory approvals; general business and economic conditions; theCompany’s ability to successfully out license or sell its currentproducts and in-license and develop new products; the assumption thatthe Company’s current good relationships with third parties will bemaintained; the availability of financing on reasonable terms; theCompany’s ability to attract and retain skilled staff; marketcompetition; the products and technology offered by the Company’scompetitors; the impact of the coronavirus (COVID-19) on theCompany’s operations; and the Company’s ability to protect patentsand proprietary rights. In evaluating forward looking statements,current and prospective shareholders should specifically considervarious factors set out herein and under the heading “RiskFactors” in the Company’s Annual Information Form dated May 1,2023, a copy of which is available on Aequus’ profile on the SEDARwebsite at www sedarplus.ca , and asotherwise disclosed from time to time on Aequus’ SEDAR profile.Should one or more of these risks or uncertainties, or a risk that isnot currently known to us materialize, or should assumptionsunderlying those forward-looking statements prove incorrect, actualresults may vary materially from those described herein. Theseforward-looking statements are made as of the date of this release andwe do not intend, and do not assume any obligation, to update theseforward-looking statements, except as required by applicablesecurities laws. Investors are cautioned that forward-lookingstatements are not guarantees of future performance and are inherentlyuncertain. Accordingly, investors are cautioned not to put unduereliance on forward looking statements.
On behalf of the Board of Directors,
“Douglas Janzen”
Director & CEO
Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906
Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX-V) accepts responsibility for the adequacy oraccuracy of this news release.
Copyright (c) 2024 TheNewswire - All rights reserved.